Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? - A systematic review

Madlaina Scharplatz, Milo A. Puhan, Johann Steurer, Annalisa Perna, Lucas M. Bachmann

Research output: Contribution to journalArticle

Abstract

Background: Pharmacogenetic testing to individualize ACE inhibitor therapy remains controversial. We conducted a systematic review to assess the effect modification of the insertion/deletion (I/D) polymorphism of the ACE gene on any outcome in patients treated with ACE inhibitors for cardiovascular and/or renal disease. Methods: Our systematic review involved searching six electronic databases, then contacting the investigators (and pharmaceutical industry representatives) responsible for the creation of these databases. Two reviewers independently selected relevant randomized, placebocontrolled trials and abstracted from each study details on characteristics and quality. Results: Eleven studies met our inclusion criteria. Despite repeated efforts to contact authors, only four of the eleven studies provided sufficient data to quantify the effect modification by genotypes. We observed a trend towards better response to ACE inhibitors in Caucasian DD carriers compared to II carriers, in terms of blood pressure, proteinuria, glomerular filtration rate, ACE activity and progression to end-stage renal failure. Pooling of the results was inappropriate, due to heterogeneity in ethnicity, clinical domains and outcomes. Conclusions: Lack of sufficient genetic data from the reviewed studies precluded drawing any convincing conclusions. Better reporting of genetic data are needed to confirm our preliminary observations concerning better response to ACE inhibitors among Caucasian DD carriers as compared to II carriers.

Original languageEnglish (US)
Article number16
JournalCurrent Controlled Trials in Cardiovascular Medicine
Volume6
DOIs
StatePublished - Oct 24 2005
Externally publishedYes

Fingerprint

Enzyme Therapy
Insertional Mutagenesis
Gene Deletion
Peptidyl-Dipeptidase A
Angiotensin-Converting Enzyme Inhibitors
Databases
Drug Industry
Glomerular Filtration Rate
Proteinuria
Chronic Kidney Failure
Research Design
Genotype
Research Personnel
Blood Pressure
Kidney
Genes

Keywords

  • ACE I/D polymorphism
  • Angiotensin-converting enzyme
  • Pharmacogenetics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? - A systematic review. / Scharplatz, Madlaina; Puhan, Milo A.; Steurer, Johann; Perna, Annalisa; Bachmann, Lucas M.

In: Current Controlled Trials in Cardiovascular Medicine, Vol. 6, 16, 24.10.2005.

Research output: Contribution to journalArticle

@article{62f611d034104351a170861e50155926,
title = "Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? - A systematic review",
abstract = "Background: Pharmacogenetic testing to individualize ACE inhibitor therapy remains controversial. We conducted a systematic review to assess the effect modification of the insertion/deletion (I/D) polymorphism of the ACE gene on any outcome in patients treated with ACE inhibitors for cardiovascular and/or renal disease. Methods: Our systematic review involved searching six electronic databases, then contacting the investigators (and pharmaceutical industry representatives) responsible for the creation of these databases. Two reviewers independently selected relevant randomized, placebocontrolled trials and abstracted from each study details on characteristics and quality. Results: Eleven studies met our inclusion criteria. Despite repeated efforts to contact authors, only four of the eleven studies provided sufficient data to quantify the effect modification by genotypes. We observed a trend towards better response to ACE inhibitors in Caucasian DD carriers compared to II carriers, in terms of blood pressure, proteinuria, glomerular filtration rate, ACE activity and progression to end-stage renal failure. Pooling of the results was inappropriate, due to heterogeneity in ethnicity, clinical domains and outcomes. Conclusions: Lack of sufficient genetic data from the reviewed studies precluded drawing any convincing conclusions. Better reporting of genetic data are needed to confirm our preliminary observations concerning better response to ACE inhibitors among Caucasian DD carriers as compared to II carriers.",
keywords = "ACE I/D polymorphism, Angiotensin-converting enzyme, Pharmacogenetics",
author = "Madlaina Scharplatz and Puhan, {Milo A.} and Johann Steurer and Annalisa Perna and Bachmann, {Lucas M.}",
year = "2005",
month = "10",
day = "24",
doi = "10.1186/1468-6708-6-16",
language = "English (US)",
volume = "6",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? - A systematic review

AU - Scharplatz, Madlaina

AU - Puhan, Milo A.

AU - Steurer, Johann

AU - Perna, Annalisa

AU - Bachmann, Lucas M.

PY - 2005/10/24

Y1 - 2005/10/24

N2 - Background: Pharmacogenetic testing to individualize ACE inhibitor therapy remains controversial. We conducted a systematic review to assess the effect modification of the insertion/deletion (I/D) polymorphism of the ACE gene on any outcome in patients treated with ACE inhibitors for cardiovascular and/or renal disease. Methods: Our systematic review involved searching six electronic databases, then contacting the investigators (and pharmaceutical industry representatives) responsible for the creation of these databases. Two reviewers independently selected relevant randomized, placebocontrolled trials and abstracted from each study details on characteristics and quality. Results: Eleven studies met our inclusion criteria. Despite repeated efforts to contact authors, only four of the eleven studies provided sufficient data to quantify the effect modification by genotypes. We observed a trend towards better response to ACE inhibitors in Caucasian DD carriers compared to II carriers, in terms of blood pressure, proteinuria, glomerular filtration rate, ACE activity and progression to end-stage renal failure. Pooling of the results was inappropriate, due to heterogeneity in ethnicity, clinical domains and outcomes. Conclusions: Lack of sufficient genetic data from the reviewed studies precluded drawing any convincing conclusions. Better reporting of genetic data are needed to confirm our preliminary observations concerning better response to ACE inhibitors among Caucasian DD carriers as compared to II carriers.

AB - Background: Pharmacogenetic testing to individualize ACE inhibitor therapy remains controversial. We conducted a systematic review to assess the effect modification of the insertion/deletion (I/D) polymorphism of the ACE gene on any outcome in patients treated with ACE inhibitors for cardiovascular and/or renal disease. Methods: Our systematic review involved searching six electronic databases, then contacting the investigators (and pharmaceutical industry representatives) responsible for the creation of these databases. Two reviewers independently selected relevant randomized, placebocontrolled trials and abstracted from each study details on characteristics and quality. Results: Eleven studies met our inclusion criteria. Despite repeated efforts to contact authors, only four of the eleven studies provided sufficient data to quantify the effect modification by genotypes. We observed a trend towards better response to ACE inhibitors in Caucasian DD carriers compared to II carriers, in terms of blood pressure, proteinuria, glomerular filtration rate, ACE activity and progression to end-stage renal failure. Pooling of the results was inappropriate, due to heterogeneity in ethnicity, clinical domains and outcomes. Conclusions: Lack of sufficient genetic data from the reviewed studies precluded drawing any convincing conclusions. Better reporting of genetic data are needed to confirm our preliminary observations concerning better response to ACE inhibitors among Caucasian DD carriers as compared to II carriers.

KW - ACE I/D polymorphism

KW - Angiotensin-converting enzyme

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=27844449987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844449987&partnerID=8YFLogxK

U2 - 10.1186/1468-6708-6-16

DO - 10.1186/1468-6708-6-16

M3 - Article

C2 - 16242049

AN - SCOPUS:27844449987

VL - 6

JO - Trials

JF - Trials

SN - 1745-6215

M1 - 16

ER -